Literature DB >> 2752978

Estradiol effects on proliferation, messenger ribonucleic acid for collagen and insulin-like growth factor-I, and parathyroid hormone-stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones.

M Ernst1, J K Heath, G A Rodan.   

Abstract

Estradiol (E2) replacement therapy effectively prevents or delays postmenopausal bone loss, but the mode of E2 action on bone is still unknown. Recently, the presence of E2 receptors was described for bone-derived cells. In this study we examined the estrogen responsiveness of osteoblastic cells using the experimentally immortalized calvarial cell lines RCT-1 and RCT-3 as well as primary cultures of calvarial and trabecular bone cells. E2 treatment reduced PTH-stimulated adenylate cyclase activity by 20-30% in RCT cells; the maximum effect was observed after treatment with 1 nM E2 for 4 h or longer. In trabecular cells E2 decreased PTH-stimulated adenylate cyclase activity by 60-80%. After a lag period of at least 48 h, E2 treatment (0.01-10 nM) increased cell number and [3H]thymidine incorporation in both RCT-3 cells and primary cultures of trabecular cells to 20-60% above control values. Half-maximal effects were observed at about 1 nM E2. Antibodies against insulin-like growth factor-I (IGF-I) inhibited the E2-induced proliferation in a dose-dependent manner without affecting basal growth. Furthermore, E2 treatment increased the steady state levels of IGF-I mRNA 2- to 2.5-fold in calvarial and RCT-3 cells compared to control levels. In addition, E2 (10 nM) increased the level of collagen mRNA more than 2-fold and opposed the suppression of collagen mRNA produced by PTH treatment. The E2 effects were specific to 17 beta-E2, since they were not observed with the biologically less active stereoisomer 17 alpha-E2 and were blocked by the E2 antagonist tamoxifen (1 microM). Thus, for osteoblastic cells in culture, E2 can directly stimulate proliferation as well as collagen and IGF-I mRNA while decreasing PTH responsiveness; these effects could explain the anabolic and anticatabolic effects of E2 on bone.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2752978     DOI: 10.1210/endo-125-2-825

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  40 in total

Review 1.  Skeletal effects of estrogens.

Authors:  G Fiorelli; M L Brandi
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

2.  Immunoelectron microscopic demonstration of estrogen receptors in osteogenic cells of Japanese quail.

Authors:  T Ohashi; S Kusuhara; K Ishida
Journal:  Histochemistry       Date:  1991

3.  Estrogen target cells during the early stage of medullary bone osteogenesis: immunohistochemical detection of estrogen receptors in osteogenic cells of estrogen-treated male Japanese quail.

Authors:  T Ohashi; S Kusuhara; K Ishida
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

4.  Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone.

Authors:  C J Jagger; J W Chow; T J Chambers
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

Review 5.  The role of leptin in regulating bone metabolism.

Authors:  Jagriti Upadhyay; Olivia M Farr; Christos S Mantzoros
Journal:  Metabolism       Date:  2014-10-25       Impact factor: 8.694

6.  Effects of rhIGF-I administration on bone turnover during short-term fasting.

Authors:  S K Grinspoon; H B Baum; S Peterson; A Klibanski
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

7.  Proliferative responses to estradiol, IL-1 alpha and TGF beta by cells expressing alkaline phosphatase in human osteoblast-like cell cultures.

Authors:  D J Rickard; M Gowen; B R MacDonald
Journal:  Calcif Tissue Int       Date:  1993-03       Impact factor: 4.333

8.  17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens.

Authors:  G Girasole; R L Jilka; G Passeri; S Boswell; G Boder; D C Williams; S C Manolagas
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

9.  Effects of estrogen replacement on insulin-like growth factor I concentrations in serum and bone tissue and on interleukin 1 secretion from spleen macrophages in oophorectomized rats.

Authors:  F Sato; Y Ouchi; A Masuyama; T Nakamura; T Hosoi; Y Okamoto; N Sasaki; M Shiraki; H Orimo
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

10.  Bone phenotypes in response to gonadotropin misexpression: the role for gonadotropins in postmenopausal osteoporosis.

Authors:  Jason P Mansell
Journal:  Int J Gen Med       Date:  2008-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.